252 related articles for article (PubMed ID: 25450326)
21. Consensus document on the management of the atherogenic dyslipidaemia of the Spanish Society of Arteriosclerosis.
Ascaso JF; Millán J; Hernández-Mijares A; Blasco M; Brea Á; Díaz Á; Mantilla T; Pedro-Botet J; Pintó X;
Clin Investig Arterioscler; 2017; 29(2):86-91. PubMed ID: 28185675
[TBL] [Abstract][Full Text] [Related]
22. [Dyslipidemia and atherogenic risk in patients with rheumatoid arthritis].
Batún Garrido JA; Olán F; Hernández Núñez É
Clin Investig Arterioscler; 2016; 28(3):123-31. PubMed ID: 27026386
[TBL] [Abstract][Full Text] [Related]
23. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
24. Urban-rural differences in atherogenic dyslipidaemia (URDAD Study): a retrospective report on diabetic and non-diabetic subjects of Northern India.
Agrawal P; Reddy VS; Madaan H; Patra SK; Garg R
J Health Popul Nutr; 2014 Sep; 32(3):494-502. PubMed ID: 25395912
[TBL] [Abstract][Full Text] [Related]
25. [Fibrates therapy: Rational use fenofibrate 2016. Executive summary].
Brea A; Millán J; Ascaso JF; Blasco M; Díaz A; González-Santos P; Hernández-Mijares A; Mantilla T; Pedro-Botet JC; Pintó X;
Clin Investig Arterioscler; 2016; 28(6):295-301. PubMed ID: 27609708
[TBL] [Abstract][Full Text] [Related]
26. [Importance of dyslipidaemia in cardiovascular disease: a point of view].
Ascaso JF; Carmena R
Clin Investig Arterioscler; 2015; 27(6):301-8. PubMed ID: 26363575
[TBL] [Abstract][Full Text] [Related]
27. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus.
Ginsberg HN; MacCallum PR
J Cardiometab Syndr; 2009; 4(2):113-9. PubMed ID: 19614799
[TBL] [Abstract][Full Text] [Related]
28. The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes.
Gonna H; Ray KK
Diabetes Obes Metab; 2019 Apr; 21 Suppl 1():6-16. PubMed ID: 31002453
[TBL] [Abstract][Full Text] [Related]
29. Elevated triglycerides and low high-density lipoprotein cholesterol level as marker of very high risk in type 2 diabetes.
Hermans MP; Valensi P
Curr Opin Endocrinol Diabetes Obes; 2018 Apr; 25(2):118-129. PubMed ID: 29493554
[TBL] [Abstract][Full Text] [Related]
30. Belgian expert opinion: how to reduce the residual risk in atherogenic dyslipidaemic patients: place of fibrates.
Ducobu J; Scheen A; Van Gaal L; Velkeniers B; Hermans M
Acta Cardiol; 2008 Apr; 63(2):235-48. PubMed ID: 18468206
[TBL] [Abstract][Full Text] [Related]
31. Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study.
Leiter LA; Lundman P; da Silva PM; Drexel H; Jünger C; Gitt AK;
Diabet Med; 2011 Nov; 28(11):1343-51. PubMed ID: 21679231
[TBL] [Abstract][Full Text] [Related]
32. Recent advances in the treatment of atherogenic dyslipidemia in type 2 diabetes mellitus.
Wanner C; Krane V
Kidney Blood Press Res; 2011; 34(4):209-17. PubMed ID: 21691123
[TBL] [Abstract][Full Text] [Related]
33. [The fixed combination of pravastatin and fenofibrate: what can it provide?].
Díaz Rodríguez Á
Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():12-6. PubMed ID: 25043541
[TBL] [Abstract][Full Text] [Related]
34. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.
Steinmetz A
Diabetes Metab Res Rev; 2008; 24(4):286-93. PubMed ID: 18273835
[TBL] [Abstract][Full Text] [Related]
35. [Atherogenic dyslipidemia: a multidisciplinary consensus panel].
Foro Dislipidemia Aterogénica
Clin Investig Arterioscler; 2013; 25(2):83-91. PubMed ID: 23747118
[TBL] [Abstract][Full Text] [Related]
36. High-Risk Atherosclerosis and Metabolic Phenotype: The Roles of Ectopic Adiposity, Atherogenic Dyslipidemia, and Inflammation.
Lechner K; McKenzie AL; Kränkel N; Von Schacky C; Worm N; Nixdorff U; Lechner B; Scherr J; Weingärtner O; Krauss RM
Metab Syndr Relat Disord; 2020 May; 18(4):176-185. PubMed ID: 32119801
[TBL] [Abstract][Full Text] [Related]
37. [Diabetic dyslipoproteinemia: beyond LDL].
Merkel M
Dtsch Med Wochenschr; 2009 May; 134(20):1067-73. PubMed ID: 19421932
[TBL] [Abstract][Full Text] [Related]
38. Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient.
Watts GF; Karpe F
Heart; 2011 Mar; 97(5):350-6. PubMed ID: 21296781
[TBL] [Abstract][Full Text] [Related]
39. [Dyslipemia in diabetics treated with statins. Results of the DYSIS study in Spian].
Millán J; Alegría E; Guijarro C; Lozano JV; Vitale GC; González-Timón B; González-Juanatey JR
Med Clin (Barc); 2013 Nov; 141(10):430-6. PubMed ID: 23246165
[TBL] [Abstract][Full Text] [Related]
40. Early-onset type 2 diabetes: higher burden of atherogenic apolipoprotein particles during statin treatment.
Song SH; Gray TA
QJM; 2012 Oct; 105(10):973-80. PubMed ID: 22753665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
